BioSpace News Archive

PetDx® announced a collaboration with IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, to significantly broaden access to canine cancer liquid biopsy testing.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced an expansion of its partnership with the Bill & Melinda Gates Foundation to include the advancement of innovative platform technologies in the development of broadly neutralizing antibodies designed to provide a “vaccinal effect” for the treatment of HIV and prevention of malaria.

Fresenius Kidney Care, the nation’s leading provider of kidney care services, and Biim Ultrasound AS (Biim), announce an agreement to expand use of Biim’s innovative ultrasound system for assisting needle cannulation prior to dialysis treatment.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), announced today that CoSara Diagnostics Pvt Ltd (“CoSara,” or the “JV”), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization (“CDSCO”) in India to manufacture and sell its SARAGENE™ Human Papillomavirus High-Risk (HPV-HR) Real-Time PCR test as an in vitro diagnostic (“IVD”).

PreveCeutical commenced its own action against some of the defendants to the Action claiming damages for fraud, conspiracy, breach of contract, and other wrongs with respect to the same transactions which are the subject of the claims asserted in the Action (the “PreveCeutical Action”).

Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.

Amoy Diagnostics Co., Ltd., (“AmoyDx”) and PREMIA Holdings (HK) Limited (“PREMIA”) today announced the commercial launch of the AmoyDx® Pan Lung Cancer PCR Panel (the “PLC Panel”) in Japan as a reimbursed companion diagnostic for multiple anti-cancer agents.

Accuredit Therapeutics announced a strategic partnership to establish a joint venture, Napoltec Life Sciences (Suzhou) Co., Ltd,

Halberd, Inc., an innovative biotech company focused on developing treatments for difficult-to-cure debilitating diseases, announces that they have been able to successfully eliminate Beta Amyloid and Interleukin-4 from synthetic cerebral spinal fluid in its latest in-vitro laboratory testing.

Predictive Oncology Inc. (NASDAQ: POAI) reported the preliminary results of its Discovery 2021 program today, announcing that its Helomics subsidiary’s evaluation demonstrated their proprietary Artificial Intelligence (AI) program CoRE™ (Computational Research Engine), combined with their tumor profile data and matched ovarian cancer samples, could identify potential new chemotherapy drug uses.